Remsima (infliximab biosimilar) for subcutaneous injection for managing Crohn’s disease and ulcerative colitis
Evidence summary
Summary (source: NICE)
Reference: ES35
Type: Evidence summary
Published: 24 February 2021
Issued by: National Institute for Health and Care Excellence (NICE)
Full guidance: Read on nice.org.uk →
Remsima (infliximab biosimilar) for subcutaneous injection for managing Crohn's disease and ulcerative colitis is evidence summary ES35, issued by the National Institute for Health and Care Excellence (NICE), which produces evidence-based recommendations for health and care in England.
Note: NICE guidance is published under a licence that applies to the UK and does not permit republication of the full text. This page provides the reference and a direct link to the official document. Read the full guidance on nice.org.uk →
Substances mentioned in this guidance
Document official
Official summary published by the National Institute for Health and Care Excellence (nice.org.uk), last published 24 February 2021. Indicative information for healthcare professionals — refer to the full document. Reference and link only, per NICE licence.